1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Drugs In Development, 2022, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 6, 2, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Aplastic Anemia - Overview
- Aplastic Anemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Aplastic Anemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Aplastic Anemia - Companies Involved in Therapeutics Development
- Aplastic Anemia - Drug Profiles
- Aplastic Anemia - Dormant Projects
- Aplastic Anemia - Discontinued Products
- Aplastic Anemia - Product Development Milestones
- Featured News & Press Releases
- May 12, 2021: Regen Biopharma announces consulting agreement with Biotech Research Group
- Jan 11, 2021: Gamida Cell to present full data from phase 3 Study of omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
- Dec 14, 2020: Gamida Cell provides regulatory update on Biologics License Application for Omidubicel
- Dec 09, 2020: Gamida Cell provides pipeline update, including detailed results of pivotal phase 3 clinical study of omidubicel, and prepares to start BLA submission by end of 2020
- Nov 04, 2020: Gamida cell announces data on omidubicel to be presented at 62nd ASH Annual Virtual Meeting
- Apr 21, 2020: Hemogenyx Pharmaceuticals announces approval and issuance of European Hu-PHEC Patent
- Feb 11, 2020: Hemogenyx Pharmaceuticals: Approval and issuance of U.S. Hu-PHEC Patent
- Oct 17, 2019: The CHMP adopted a negative opinion recommending the refusal of a marketing authorisation for Revolade (eltrombopag)
- Aug 01, 2019: Health ministry to reimburse Novartis’ Revolade treating severe aplastic anemia
- Jun 28, 2019: Refusal of a change to the marketing authorisation for Revolade (eltrombopag)
- Jun 25, 2019: Novartis has requested a re-examination of EMA’s opinion on Revolade
- Jun 18, 2019: Kyowa Hakko Kirin receives the partial change approval of Romiplate for Aplastic Anemia in Japan
- May 11, 2019: Novartis issues voluntary nationwide recall of Promacta 12.5 mg for oral suspension due to potential peanut contamination
- Feb 21, 2019: Gamida cell presents initial data from phase 1/2 study of NiCord in severe aplastic anemia at 2019 TCT Annual Meeting
- Feb 14, 2019: Gamida Cell to host conference call and webcast to review data from NiCord program being presented at 2019 TCT Annual Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Aplastic Anemia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Aplastic Anemia - Pipeline by Acceleron Pharma Inc, 2022
- Aplastic Anemia - Pipeline by Amgen Inc, 2022
- Aplastic Anemia - Pipeline by ASC Therapeutics Inc, 2022
- Aplastic Anemia - Pipeline by Bellicum Pharmaceuticals Inc, 2022
- Aplastic Anemia - Pipeline by BioLineRx Ltd, 2022
- Aplastic Anemia - Pipeline by Cell Source Inc, 2022
- Aplastic Anemia - Pipeline by Cellenkos Inc, 2022
- Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Aplastic Anemia - Pipeline by Gamida Cell Ltd, 2022
- Aplastic Anemia - Pipeline by Hangzhou Zede Pharmaceutical Technology Co Ltd, 2022
- Aplastic Anemia - Pipeline by HemoGenyx Pharmaceuticals Plc, 2022
- Aplastic Anemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Aplastic Anemia - Pipeline by Novartis AG, 2022
- Aplastic Anemia - Pipeline by Ono Pharmaceutical Co Ltd, 2022
- Aplastic Anemia - Pipeline by Pfizer Inc, 2022
- Aplastic Anemia - Pipeline by Regen BioPharma Inc, 2022
- Aplastic Anemia - Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Aplastic Anemia - Dormant Projects, 2022
- Aplastic Anemia - Discontinued Products, 2022
- Number of Products under Development for Aplastic Anemia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acceleron Pharma Inc
- Amgen Inc
- ASC Therapeutics Inc
- Bellicum Pharmaceuticals Inc
- BioLineRx Ltd
- Cell Source Inc
- Cellenkos Inc
- F. Hoffmann-La Roche Ltd
- Gamida Cell Ltd
- Hangzhou Zede Pharmaceutical Technology Co Ltd
- HemoGenyx Pharmaceuticals Plc
- Jiangsu Hengrui Medicine Co Ltd
- Novartis AG
- Ono Pharmaceutical Co Ltd
- Pfizer Inc
- Regen BioPharma Inc
- Regeneron Pharmaceuticals Inc
